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Aims To evaluate arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) in affected families with desmo-
some mutations on the basis of the recently revised Task Force Criteria (TFC).
Methods
and results
One hundred and three consecutive carriers of pathogenic desmosome mutations and 102 mutation-negative rela-
tives belonging to 22 families with dominant and 14 families with recessive ARVC/D were evaluated according to the
original and revised TFC. Serial cardiac assessment with 12-lead, signal-averaged, and 24 h ambulatory ECG and two-
dimensional echocardiography was performed. Clinical events and outcome were prospectively analysed up to 24
years (median 4 years). With the revised criteria, 16 carriers were newly diagnosed on the basis of ECG abnormalities
in 100%, ventricular arrhythmias in 79%, and functional/structural alterations in 31%, increasing diagnostic sensitivity
from 57 to 71% (P ¼ 0.001). Task Force Criteria speciﬁcity improved from 92 to 99% (P ¼ 0.016). In dominant
mutation carriers, penetrance changed signiﬁcantly (61 vs. 42%, P ¼ 0.001); no changes were observed in recessive
homozygous carriers (97 vs. 97%, P ¼ 1.00). Affected carriers according to the revised TFC (n ¼ 73) had 12-lead
ECG abnormalities in 96%, ventricular arrhythmias in 91%, and functional/structural alterations fulﬁlling echocardio-
graphic criteria in 76%. Cumulative and event-free survival did not differ signiﬁcantly between dominant and recessive
affected carriers, being at 78.6 vs. 76 and 51.7 vs. 55.4%, respectively, by the age of 40 years.
Conclusion Revised TFC increased diagnostic sensitivity particularly in dominant ARVC/D. Serial family evaluation may rely on
electrocardiography which seems to have the best diagnostic utility particularly in early disease that is not detectable
by two-dimensional echocardiography.
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Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is a primary heart muscle disorder presenting clinically
with ventricular arrhythmias, sudden death, or heart failure and
characterized pathologically by progressive myocardial loss with
ﬁbrous or ﬁbrofatty replacement mostly of the right ventricle.
1,2
In the absence of a clinical gold standard for the diagnosis of
ARVC/D, in 1994, the International Task Force Criteria (TFC)
was established.
3 The original TFC focused on the diagnosis of
overt and severe disease and lacked sensitivity for early forms
common among family members. In a recent modiﬁcation which
included quantitative parameters, it was aimed to improve diagnos-
tic sensitivity with the important requisite of maintaining
speciﬁcity.
4
Arrhythmogenic right ventricular cardiomyopathy/dysplasia is a
genetically determined disorder of the desmosomal plaque which
in  50% of probands is associated with mutations of desmosomal
proteins plakoglobin (JUP), desmoplakin (DSP), plakophilin-2
(PKP2), desmoglein-2, and desmocollin-2 (DSC2).
5–9 The mode
of inheritance is usually dominant with reduced penetrance.
6–9 A
recessive form due to JUP mutation associated with a cutaneous
phenotype (Naxos disease) has been reported to show full pene-
trance by adolescence.
5,10 This form of the disease permits testing
of TFC diagnostic sensitivity and studying the mode of disease
onset.
11
This study evaluated the recently revised TFC for the diagnosis
of ARVC/D comparing them with the original ones in affected
families with dominant and recessive desmosome gene mutations.
Age-related penetrance and disease expression were assessed by
applying the revised TFC.
Methods
The study population included 103 consecutive carriers of pathogenic
desmosome mutations and 102 mutation-negative relatives (ﬁrst- and
second-degree) belonging to 36 families with dominant (n ¼ 22) and
recessive (n ¼ 14) ARVC/D (members per family: median 3.5, inter-
quartile range: 3–5) (see Supplementary material online, Figure S1).
The proband in each family met TFC for the diagnosis of ARVC/D;
31 probands met the original plus revised TFC, whereas ﬁve met
only the revised TFC. Of the 36 probands, 22 were carriers of domi-
nant mutations (11 of PKP2, 4 of DSP, 6 of DSC2, and 1 of PKP2 plus
DSP) and 14 were homozygous carriers of the known recessive JUP
mutation (Naxos disease).
5 All family members were screened for
the probands’ mutations by direct sequencing as described previously.
9
None of the identiﬁed sequence variants were present in a cohort of
400 control chromosomes. Sequence variants were deﬁned as patho-
genic as detailed in the revised TFC.
4
All individuals underwent cardiac assessment including a detailed
history of cardiac events, physical examination, resting 12-lead ECG,
24 h ambulatory ECG, signal-averaged ECG (SAECG), and two-
dimensional echocardiography. These investigations were performed
every 12 months or more frequent in those with clinical events in a
prospective follow-up of up to 24 years (median 4 years, inter-quartile
range: 3–6). Myocardial tissue was available in 13 patients (4 endomyo-
cardial, 3 surgical, and 6 post-mortem). The original and revised TFC
(see Supplementary material online, Table S1) were applied to all
examined individuals.
3,4 The diagnosis of ARVC/D was fulﬁlled by
the presence of two major or one major plus two minor or four
minor criteria from different categories. The study complies with the
Declaration of Helsinki, the locally appointed Ethics Committee
approved the research protocol, and informed consent was obtained
from all individuals. Clinical events and outcome were recorded by
age. Detailed historical data were available from medical records.
Electrocardiography and echocardiography
All ECGs were recorded at rest (10 mm/mV in speed 25 mm/s) at the
standard lead position. No individual was receiving antiarrhythmic or
other drugs known to affect the QRS complex at the time of acqui-
sition of the ECG trainings. To increase the accuracy of measurements,
ECGs were enlarged three times. Digital callipers capable of measuring
to within 0.1 mm (4 ms) in the horizontal axis and 0.1 mm (0.01 mV) in
the vertical axis were used to determine the intervals (Adobe Photo-
shop CS3). QRS complex duration in leads V1 to V6 and terminal acti-
vation duration (TAD) of QRS complex in leads V1 to V3 (from the
nadir of the S-wave to the end of the QRS, including R′) were
measured in three consecutive beats in each lead according to the pro-
tocol described by Nasir et al.
12; the mean value of the three beats was
used. Epsilon waves and T-wave inversion were studied on precordial
leads.
4 Signal-averaged ECG was performed using time-domain analysis
with a band-pass ﬁlter of 40 Hz in individuals with a QRS complex dur-
ation of ,110 ms on standard ECG. It was considered positive for late
potentials if at least two of the three parameters for original TFC or
one for revised TFC was abnormal.
4 A 24 h ambulatory ECG was
recorded on an outpatient basis. Ventricular extrasystoles and epi-
sodes of ventricular tachycardia (three or more consecutive ventricu-
lar complexes at a rate of ≥100 b.p.m.) were noted. The morphology
and axis of non-sustained or sustained (lasting .30 s) ventricular
tachycardia was determined when three of more lead ECG recordings
were available.
Echocardiography was performed with a 2.5 MHz transducer. Right
ventricular size was estimated in two-dimensional echocardiographic
recordings at the end of diastole. In particular, right ventricular
outﬂow tract diameter was measured on the parasternal long-axis
view (RVOT-PLAX) and right ventricular inﬂow tract (RVIT) diameter
on apical four-chamber view according to the protocol by Foale et al.
13
Wall motion abnormalities of the right ventricle (hypokinesia, akinesia,
dyskinesia, and aneurysm) were documented. Severe hypokinesia was
classiﬁed as akinesia. Aneurysm was deﬁned as an akinetic or dyskinetic
area with diastolic bulging.
3
All measurements were performed by the same investigator (N.P.),
before the result of mutation analysis was known. The repeatability of
all measurements was tested in random samples of 25 ECG and 25
echocardiographic recordings; the 95% Bland–Altman limits ranged
from 26.4 to 3.9 ms for QRS complex width, from 24.1 to 3.7 ms
for TAD, from 21.6 to 1.8 mm for RVOT-PLAX, and from 22.2 to
3.1 mm for RVIT. Normal limits of RVOT-PLAX and RVIT were
deﬁned by the assessment of 140 healthy Greek volunteers (70 men
and 70 women) aged 39+13 years (range: 13–66 years). Right ven-
tricular dilatation was classiﬁed as minor (2–3 SD from normal
values) or major (more than 3 SD from normal values) according to
the original TFC (see Supplementary material online, Table S2).
3 Apply-
ing the revised TFC, right ventricular dilatation was classiﬁed as minor
(RVOT-PLAX ≥29 to ,32 mm) and major (RVOT-PLAX ≥32 mm)
according to the reported cut-off points.
4
Statistical analysis
Summary descriptive statistics are reported as mean+SD, or fre-
quency counts and %, as appropriate. Intra-observer variability for
N. Protonotarios et al. 1098randomly selected ECG/echocardiographic recordings was assessed
with the Bland–Altman method. Sensitivity and speciﬁcity were com-
pared using the McNemar test. The Kaplan–Meier event-free survival
curves were constructed and compared with the log-rank test. SPSS 17
was used for all analyses. All statistical tests were performed at the
two-sided 5% level of signiﬁcance.
Results
Revised vs. original Task Force Criteria
for diagnosis of arrhythmogenic right
ventricular cardiomyopathy/dysplasia
Fifty-nine of 103 (57%) mutation carries (see Supplementary
material online, Table S3) and 8 of 102 (8%) mutation-negative
family members (see Supplementary material online, Table S4) ful-
ﬁlled the original TFC. Applying modiﬁed criteria one by one, the
rate of diagnosis signiﬁcantly changed by modifying Criterion VI
(family history/genetics) (Table 1). Applying proposed modiﬁ-
cations of all six TFC, 16 additional carriers were diagnosed, but
2 other carriers fulﬁlling the original TFC were missed, increasing
diagnostic sensitivity from 57 to 71% (P ¼ 0.001) (Tables 1 and
2). In particular, diagnostic sensitivity was signiﬁcantly increased
in carriers of dominant mutations (61 vs. 42%, P ¼ 0.001),
whereas no signiﬁcant change was observed for recessive
homozygous carriers (97 vs. 97%, P ¼ 1.000) (Table 2). Among
mutation-negative family members, application of revised TFC
excluded from diagnosis seven individuals by quantitative par-
ameters for functional/structural and depolarization abnormalities,
increasing speciﬁcity from 92 to 99% (P ¼ 0.016) (Tables 1 and 2).
Diagnosis of arrhythmogenic right
ventricular cardiomyopathy/dysplasia
according to revised Task Force Criteria
Seventy-three mutation carriers (55% male) aged 40+18 years
(range: 12–77) fulﬁlled the revised TFC (affected carriers) (see
Supplementary material online, Table S3): 10 fulﬁlled one major
plus at least two minor criteria, whereas the other 63 fulﬁlled at
least two major criteria. Forty-ﬁve were carriers of dominant
mutations and 28 were homozygous carriers of the recessive
JUP mutation. All 16 of the newly diagnosed individuals had ECG
abnormalities, whereas 79% also had ventricular arrhythmias; func-
tional/structural alterations fulﬁlling echocardiographic criteria
were detected in 31%.
Thirty mutation carriers (43% male) aged 48+17 years (range:
16–84) at last follow-up did not fulﬁl the revised TFC (non-
affected carriers). Twelve of them fulﬁlled one minor criterion
besides family history/genetics: 10 had minor depolarization
abnormalities and two had ventricular extrasystoles .500/24 h.
None developed symptoms during follow-up. Two carriers met
........................................................... ...........................................................
...............................................................................................................................................................................
Table 1 Changes in diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia applying modiﬁcations of
Task Force Criteria
Modiﬁcations of Task Force Criteria Mutation carriers (n 5 103) Mutation-negative (n 5 102)
New diagnosed Missed diagnosis P-value
a New diagnosed Missed diagnosis P-value
a
Criterion I (functional/structural alterations) 2 6 0.289 0 3 0.250
Criterion II (tissue characterization) 0 0 1.000 0 0 1.000
Criterion III (repolarization abnormalities) 4 0 0.125 0 0 1.000
Criterion IV (depolarization abnormalities) 4 2 0.688 0 4 0.125
Criterion V (arrhythmias) 4 0 0.125 0 0 1.000
Criterion VI (family history/genetics) 13 0 ,0.001 0 0 1.000
Criteria I to VI (all modiﬁcations) 16 2 0.001 0 7 0.016
aTask Force Criteria with modiﬁcations vs. original ones.
......................................... ............................................
...............................................................................................................................................................................
Table 2 Comparison of revised to original Task Force Criteria to diagnose arrhythmogenic right ventricular
cardiomyopathy/dysplasia in 205 individuals
Demographics Individuals fulﬁlling TFC P-value
Age (years) Male:female Original TFC Revised TFC
Mutation carriers (n ¼ 103) 41+18 52:51 59 (57) 73 (71) 0.001
Dominant mutation carriers (n ¼ 74) 42+17 37:37 31 (42) 45 (61) 0.001
Recessive mutation carriers (n ¼ 29) 41+18 15:14 28 (97) 28 (97) 1.000
Mutation-negative family members (n ¼ 102) 41+16 47:55 8 (8) 1 (1) 0.016
Values are n (%). TFC, Task Force Criteria.
ARVC/D in affected families with desmosome mutations 1099the original TFC, but were excluded from diagnosis by the revised
quantitative echocardiographic criteria (see Supplementary
material online, Table S3, Cases 38 and 53).
Among 102 mutation-negative family members (46% male) aged
41+16 years (range 13–88), 27 had minor repolarization (n ¼ 6)
or depolarization (n ¼ 21) abnormalities. Another one, a
71-year-old woman, ﬁrst-degree relative, fulﬁlled the revised TFC
showing T-wave inversion in leads V1, V2, and V3 (see
Supplementary material online, Table S4, Case 1). None developed
arrhythmias or symptoms during follow-up.
Clinical features of affected carriers
Clinical characteristics of 73 affected carriers fulﬁlling the revised
TFC were analysed. Seventy individuals (96%) fulﬁlled 12-lead
ECG criteria. In particular, 32 (44%) had repolarization plus
depolarization abnormalities, 22 (30%) had repolarization
Figure 1 Recordings from 12-lead ECG (25 mm/s, 10 mm/mV) (top left) and signal-averaged ECG (ﬁlter 40–250 Hz) (top right) of a
12-year-old JUP homozygous carrier (see Supplementary material online, Table S3, Case 73) presenting .1000/24 h ventricular extrasystoles.
There is prolonged terminal activation duration (58 ms) in lead V1 and all three parameters for late potentials are abnormal (ﬁltered QRS
duration ¼ 125 ms, LAS ¼ 42 ms, RMS ¼ 11 mV). Two-dimensional echocardiographic images on parasternal long axis view (middle left)
and apical four-chamber view (middle right). There are no morphological/functional abnormalities of the right and left ventricle; right ventricular
end-diastolic diameters at outﬂow tract (RVOT) and inﬂow tract (RVIT) were within normal limits (corrected for body surface area, 14 and
21 mm/m
2, respectively). The boy shows the Naxos cutaneous phenotype (woolly hair and palmoplantar keratoderma) (bottom).
N. Protonotarios et al. 1100abnormalities alone, and 16 (22%) had depolarization abnormal-
ities alone. Three individuals (see Supplementary material online,
Table S3, Cases 14, 34, and 45) who did not meet 12-lead ECG cri-
teria fulﬁlled all three parameters for late potentials on SAECG.
Ventricular extrasystoles .500/24 h were recorded in 64 out of
70 individuals (91%) who underwent 24 h ambulatory ECG. Non-
sustained (n ¼ 15) or sustained (n ¼ 23) ventricular tachycardia of
left bundle branch block conﬁguration on either resting ECG, 24 h
ambulatory ECG, or stress testing was recorded in 48% of the
affected. Fifty of 66 individuals (76%) with quantitative echocardio-
graphic data showed functional/structural abnormalities which ful-
ﬁlled the revised echocardiographic criteria. In the remaining 16
individuals, right ventricular functional/structural alterations on
two-dimensional echocardiography were subdiagnostic (n ¼ 12)
or absent (n ¼ 4) (Figures 1–3). Left ventricular functional/struc-
tural alterations on two-dimensional echocardiography were
detected in 35% of the affected.
Clinical events occurred in 46 of the 73 affected (63%) (see Sup-
plementary material online, Table S3). The initial presenting event
was sustained ventricular tachycardia in 20, syncope without docu-
mented sustained ventricular tachycardia in 19, symptoms of heart
failure in 2, and sudden death in 5 at age 33+18 years (range: 12–
72). Oral antiarrhythmic treatment was applied in 39 patients, sur-
gical ablation was performed in 3, and an antitachycardia
Figure 2 Recordings from 12-lead ECG (25 mm/s, 10 mm/mV) of a 24-year-old desmoplakin mutation carrier (see Supplementary material
online, Table S3, Case 29) not diagnosed with original Task Force Criteria. During sinus rhythm (top) there is low voltage, T-wave inversion in
leads V1 (20.7 mm) and V2 (20.2 mm), normal QRS complex width (≤100 ms) in leads V1 to V3, and prolonged TAD (56 ms) in lead V2. She
presented sustained ventricular tachycardia of left bundle branch block morphology with superior axis (bottom) but she did not fulﬁl echocar-
diographic criteria.
ARVC/D in affected families with desmosome mutations 1101pacemaker deﬁbrillator was implanted in 20. Twelve affected
carriers (ﬁve carriers of dominant mutations and seven homozy-
gous carriers of the recessive mutation) developed heart failure
at age 36+15 years (range: 15–60). Eighteen patients died
prematurely from a cardiac cause (14 suddenly and 4 from
heart failure). The mean age at death was 33+13 years (range:
17–58). The Kaplan–Meier curves did not differ signiﬁcantly
between dominant and recessive affected carriers for cumulative
survival (P ¼ 0.37) and event-free survival (P ¼ 0.24) (Figure 4).
By the age of 40 years, cumulative survival for dominant and reces-
sive affected carriers was 78.6+6.8 and 76+8.3%, respectively,
whereas event-free survival was 51.7+7.9 and 55.4+9.6%,
respectively.
Discussion
The diagnosis of ARVC/D is challenging, particularly in relatives of
affected individuals in whom disease expression is often incom-
plete. Task Force Criteria established in 1994 were not sensitive
enough to diagnose ARVC/D at early stages of disease when
only a subtle phenotype may have developed, although sudden
death might be the initial presentation.
3,4 The recently modiﬁed
Figure 3 Recording from 12-lead ECG (25 mm/s, 10 mm/mV) (top) of a 18-year-old PKP2 mutation carrier (see Supplementary material
online, Table S3, Case 13) shortly before he died suddenly during sport activity. He presented .1000/24 h ventricular extrasystoles but he
did not fulﬁl echocardiographic criteria. There is T-wave inversion in leads V1 to V4 and ﬂattening in V5 and V6; abnormal Q waves are
observed in inferolateral leads. Autopsy samples (bottom) reveal mild ﬁbro-fatty replacement of the right ventricular myocardium (RV),
with predominant involvement of the left ventricular myocardium (LV), with a subepicardial and midmural distribution and a preserved wall
thickness (Heidenhain’s trichrome stain).
N. Protonotarios et al. 1102TFC aimed to increase diagnostic sensitivity with the important
requisite of maintaining speciﬁcity by including quantitative par-
ameters.
4 Cox et al.
14 published recently on the sensitivity of modi-
ﬁed TFC but not in a genotyped population. However, evaluation
of speciﬁcity needs a gold standard for diagnosis to exclude false-
positive results. In the present study, the pathogenic mutation was
considered as a gold standard for the risk of disease development
and enabled testing of speciﬁcity among mutation-negative family
members. Also, the upper limit of diagnostic sensitivity was
tested among recessive homozygous carriers in whom ARVC/D
shows full penetrance by adolescence.
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In 36 genotyped families affected by dominant and recessive
ARVC/D, modiﬁcation of TFC signiﬁcantly increased diagnostic
sensitivity without a decrease in speciﬁcity, which also improved.
In dominant ARVC/D that shows incomplete penetrance har-
bouring the risk of missing mild forms of the disease, the
revised criteria improved diagnostic accuracy and increased pene-
trance from 42 to 61%. In recessive ARVC/D showing a more
homogeneous and severe clinical expression, modiﬁcation of
TFC did not alter the existing high penetrance of 97% which
implies the upper limit of diagnostic sensitivity. The increased
diagnostic sensitivity is mostly due to modiﬁed Criterion VI
(family history/genetics) supported by modiﬁcations in Criteria
III (repolarization abnormalities) and V (arrhythmias). Improve-
ment of speciﬁcity mostly resulted from modiﬁed Criterion IV
(depolarization abnormalities) followed by modiﬁed Criterion I
(functional/structural alterations). False-positive diagnosis using
the original TFC was mainly related to right precordial lead
QRS prolongation and mild right ventricular dilatation (see Sup-
plementary material online, Table S4).
In this study, 12-lead ECG showed the highest diagnostic sensi-
tivity exceeding 95%. A recent study demonstrated perfect repro-
ducibility for repolarization abnormalities but moderate
reproducibility for depolarization abnormalities.
15 The vast
majority of our patients presented right precordial lead T-wave
inversion, whereas epsilon waves and/or terminal activation delay
was the only ECG criteria in less than one-forth of cases.
Data presented suggest that electrocardiographic and arrhyth-
mic manifestations of disease precede structural abnormalities.
The practical implication of this is that serial evaluation of asymp-
tomatic family members will produce a higher yield when focused
on serial ECG and arrhythmia detection. Failure of two-
dimensional echocardiography to detect early disease may relate
to no full thickness involvement of the myocardium that does
not result in detectable change in wall motion or dimensions of
the chamber.
16 It is possible that delayed enhancement imaging
using cardiac magnetic resonance (CMR) may be informative in
this arena, particularly in the detection of early left ventricular
involvement.
17 The ﬁnding of electrical abnormalities preceding
structural abnormalities has been noted previously and is sup-
ported by the case of the 12-year-old boy described in Figure 1,
whose initial disease manifestation was the development of ECG/
arrhythmia abnormalities in the absence of functional/structural
alterations. This conﬁrms an analogous disease presentation of
another Naxos child which has been published previously.
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Conclusions
This study demonstrates that revised TFC are more sensitive to
original ones for the diagnosis of familial ARVC/D, particularly
the dominant form. The data suggest that electrical/arrhythmic
abnormalities precede the development of morphological/func-
tional alterations on two-dimensional echocardiography; this will
have practical signiﬁcance for the serial assessment of family
members at risk of disease development.
Figure 4 The Kaplan–Meier survival curves for cumulative survival (left) and event-free survival (right) in dominant (D) (solid line) and reces-
sive (R) (dotted line) affected carriers.
ARVC/D in affected families with desmosome mutations 1103Study limitations
There are several limitations in this study. Although ARVC/D due
to desmosome mutations represents more than 50% of ARVC/D
probands and the majority of familial cases, other genetic or
acquired causes might exist. A standard and accurate protocol
was followed for measurement of QRS complex duration;
however, in other studies, this electronic method has not been
proved to be of higher reproducibility.
15 In addition, since CMR
was not achievable for all patients, functional/structural alterations
were evaluated by two-dimensional echocardiography. Although
delayed enhancement in CMR might be proved superior to two-
dimensional echocardiography in detecting early left ventricular
involvement, it has not yet been included in established criteria
for the diagnosis of ARVC/D.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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